Soligenix, Inc. (SNGX)

Trade SNGX now with
2/14/2023 7:33:30 AM Soligenix Receives Refusal To File Letter From DA For HyBryte NDA In Treatment Of Cutaneous T-Cell Lymphoma
2/9/2023 7:40:36 AM Soligenix Intends To Effect Reverse Stock Split Of Stock At A Ratio Of 1 Post-split Share For Every 15 Pre-split Shares
12/20/2022 7:36:36 AM Soligenix Announces Publication Showing Positive Correlates Of Protection With RiVax In Non-Human Primate Survival
12/15/2022 7:43:36 AM Soligenix Submits NDA For HyBryte
12/15/2022 7:34:13 AM Soligenix Submits NDA To The FDA For HyBryte In The Treatment Of Cutaneous T-cell Lymphoma
11/10/2022 7:40:16 AM Soligenix Q3 Net Loss $3.3 Mln Or $0.08/shr Vs Loss $3.6 Mln Or $0.09/shr Prior Year
10/20/2022 8:37:07 AM Soligenix : Annual Meeting Adjourned To November 17, 2022
9/23/2022 7:32:53 AM Soligenix : Annual Meeting Of Stockholders Adjourned To October 19
9/6/2022 7:32:52 AM FDA Awards $2.6 Mln Orphan Products Development Grant For Study Of HyBryte In Treatment Of Cutaneous T-Cell Lymphoma
8/12/2022 7:41:16 AM Soligenix, Inc. Q2 Net Loss/shr $0.06 Vs. Loss/shr $0.05 Last Year
7/27/2022 7:43:25 AM Soligenix Gets Agreement From FDA On Initial Pediatric Study Plan For HyBryte For Cutaneous T-Cell Lymphoma Treatment